Abstract

GEN EdgeVol. 4, No. 1 Artificial IntelligenceApriori Bio's AI Platform Provides Variant-Proof Protection from Viral ThreatsFollowing more than two years of development, Flagship Pioneering unveils Apriori Bio with $50 million of committed capital.Jonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:8 Aug 2022https://doi.org/10.1089/genedge.4.1.97AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 4Issue 1Jan 2022 Information© 2022 by GEN PublishingTo cite this article:Jonathan D Grinstein.Apriori Bio's AI Platform Provides Variant-Proof Protection from Viral Threats.GEN Edge.Jan 2022.593-597.http://doi.org/10.1089/genedge.4.1.97Published in Volume: 4 Issue 1: August 8, 2022PDF download

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.